Related Experiment Video
Updated: Mar 7, 2026
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy
Yunzhou Wu1, Jinjiao He2, Jingshu Geng3
1College of Life Science, Northeast Agriculture University, Mucai Street 59, Xiangfang District, Harbin, China.
Abstract:
Newcastle disease virus (NDV) have shown oncolytic therapeutic efficacy in preclinical studies and are currently proved for clinical trials. We have previously reported, for the first time, NDV Anhinga strain has an efficient cancer therapeutic efficacy in hepatoma. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) functions as a cytokine to selectively kill various cancer cells without toxicity to most normal cells. Numerous studies have demonstrated the potential use of recombinant soluble TRAIL as a cancer therapeutic agent. In this study, we have showed administration of a recombinant NDV Anhinga strain expressing soluble TRAIL (NDV/Anh-TRAIL) results in an efficient suppression of hepatocellular carcinoma without significant toxicity. The results show that recombinant NDV Anhinga strain expressing soluble TRAIL is a promising candidate for hepatoma therapy.
Insights
Newcastle disease virus (NDV) Anhinga strain expressing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) effectively suppressed hepatocellular carcinoma. This novel oncolytic virus therapy shows promise for hepatoma treatment with minimal toxicity.
Area of Science:
- Oncolytic virotherapy
- Cancer immunotherapy
- Hepatocellular carcinoma research
Background:
- Newcastle disease virus (NDV) Anhinga strain demonstrates oncolytic efficacy in preclinical hepatoma models.
- Recombinant soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exhibits selective cancer cell-killing properties.
- Combining NDV with TRAIL offers a potential strategy for enhanced cancer therapy.
Purpose of the Study:
- To evaluate the therapeutic efficacy of a recombinant NDV Anhinga strain expressing soluble TRAIL (NDV/Anh-TRAIL) in hepatocellular carcinoma.
- To assess the safety and toxicity profile of NDV/Anh-TRAIL therapy.
- To determine the potential of NDV/Anh-TRAIL as a novel hepatoma treatment.
Main Methods:
- Development of a recombinant NDV Anhinga strain engineered to express soluble TRAIL.
- Administration of NDV/Anh-TRAIL to hepatocellular carcinoma models.
- Evaluation of tumor suppression and assessment of systemic toxicity.
Main Results:
- NDV/Anh-TRAIL administration resulted in significant suppression of hepatocellular carcinoma growth.
- The recombinant virus demonstrated an acceptable safety profile with no significant observed toxicity.
- Effective oncolytic and therapeutic activity was observed in hepatoma models.
Conclusions:
- Recombinant NDV Anhinga strain expressing soluble TRAIL is a potent therapeutic candidate for hepatocellular carcinoma.
- This oncolytic virotherapy approach warrants further clinical investigation for hepatoma treatment.
- NDV/Anh-TRAIL offers a promising strategy for targeted cancer therapy with reduced side effects.
